FAKTOR-OPTIONSSCHEIN - INCYTE CO. | Market Closed - Börse Stuttgart 15:54:54 2024-06-28 EDT | ||
| 1.41 EUR | -12.42% |
|
| Current month | +16.53% | ||
| 1 month | +25.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.41 | -12.42% |
| 24-06-27 | 1.61 | -4.17% |
| 24-06-26 | 1.68 | -12.95% |
| 24-06-25 | 1.93 | -4.93% |
| 24-06-24 | 2.03 | +9.14% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 03:54 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB670X |
| ISIN | DE000MB670X6 |
| Date issued | 2023-05-10 |
| Strike | 51.14 $ |
| Maturity | Unlimited |
| Parity | 6.01 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.16 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.01 € |
| Spread % | 0.67% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
60.62
USD
Average target price
72.8
USD
Spread / Average Target
+20.09%
- Stock Market
- Certificates
- Certificat
